Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Key Points

• Short interest fell 20.8% in March to 114,947 shares, representing about 0.2% of the company's shares, but the short-interest ratio is an extreme 7,663.1 days due to an average daily volume of only 15 shares.
• Genmab missed EPS estimates, reporting $0.55 EPS versus $3.10 expected while revenue of $1.06 billion roughly matched forecasts; the stock trades with a market cap of $16.45 billion and a P/E of 17.26.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 114,947 shares, a drop of 20.8% from the February 26th total of 145,224 shares. Approximately 0.2% of the company's shares are short sold. Based on an average daily volume of 15 shares, the short-interest ratio is currently 7,663.1 days.

Genmab A/S Stock Performance

OTCMKTS GNMSF opened at $267.20 on Friday. The company has a market cap of $16.45 billion, a P/E ratio of 17.26 and a beta of 0.92. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The business's 50 day moving average price is $299.64 and its 200-day moving average price is $306.52. Genmab A/S has a fifty-two week low of $170.00 and a fifty-two week high of $352.00.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.10 by ($2.55). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company's core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab's science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.